CHICAGO, Sept. 29 /PRNewswire-FirstCall/ — Allscripts Healthcare
Solutions, Inc. (“Allscripts”) (Nasdaq: MDRX), the leading provider of
clinical software, connectivity and information solutions that physicians use
to improve healthcare, announced today that its Board of Directors has set
October 9, 2008 as the record date for the previously announced special cash
dividend in connection with the pending transactions with Misys plc. The
payment of the special cash dividend is contingent upon the closing of the
transactions contemplated by the Agreement and Plan of Merger dated as of
March 17, 2008 (the “Merger Agreement”) by and among Misys plc, Misys
Healthcare Systems, LLC, Allscripts and Patriot Merger Company, LLC, which is
conditioned upon, among other customary conditions, receipt of certain
approvals of Allscripts stockholders and Misys shareholders, which are being
sought at meetings scheduled for October 6, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b)
The special cash dividend will be paid from the proceeds of the share
issuance contemplated by the Merger Agreement. The approval of such share
issuance is being sought at Allscripts’ 2008 annual meeting of stockholders to
be held on October 6, 2008. The special cash dividend is in the aggregate
amount of $330,000,000; the corresponding per share amount of the special cash
dividend will not be determined until the actual number of shares of
Allscripts common stock outstanding as of the close of business on the record
date of October 9, 2008 is determined. The payment of the special cash
dividend will be made on October 17, 2008 on a pro-rata basis in respect of
all shares of Allscripts common stock outstanding as of the close of business
on the record date. Holders of Allscripts common stock who sell their shares
through the payment date also will be selling their right to receive the
special cash dividend. The ex-dividend date for the special cash dividend is
expected to be October 20, 2008.
About Allscripts
Allscripts is the leading provider of clinical software, connectivity and
information solutions that physicians use to improve healthcare. The company’s
unique solutions inform, connect and transform healthcare, delivering improved
care at lower cost. More than 40,000 physicians and thousands of other
healthcare professionals in clinics, hospitals and extended care facilities
nationwide utilize Allscripts to automate everyday tasks such as writing
prescriptions, documenting patient care, managing billing and scheduling, and
safely discharging patients, as well as to connect with key information and
stakeholders in the healthcare system. To learn more, visit Allscripts at
https://www.allscripts.com.
Additional Information and Where to Find It
This communication is being made in respect of the proposed business
combination involving a subsidiary of Allscripts and Misys Healthcare Systems,
LLC (“MHS”), a wholly owned subsidiary of Misys plc (“Misys”). In connection
with this proposed transaction, Allscripts has filed with the Securities and
Exchange Commission (the “SEC”) a definitive proxy statement. BEFORE MAKING
ANY DECISION WITH RESPECT TO THE PROPOSED TRANSACTION, INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS
WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE COMPANY AND THE PROPOSED TRANSACTION. Investors and security holders
can obtain copies of Allscripts’ materials (and all other offer documents
filed with the SEC) when available, at no charge on the SEC’s website:
http://www.sec.gov. Copies can also be obtained at no charge by directing a
request for such materials to Allscripts at 222 Merchandise Mart Plaza, Suite
2024, Chicago, Illinois 60654, Attention: Lee Shapiro, Secretary. Investors
and security holders may also read and copy any reports, statements and other
information filed by Allscripts with the SEC, at the SEC public reference room
at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-
SEC-0330 or visit the SEC’s website for further information on its public
reference room. Allscripts’ directors, executive officers and other members of
management and employees may, under the rules of the SEC, be deemed to be
participants in the solicitation of proxies from the stockholders of
Allscripts in favor of the proposed transaction. Information about Allscripts,
its directors and its executive officers, and their ownership of Allscripts’
securities, is set forth in its definitive proxy statement for the 2008 Annual
Meeting of Stockholders of the Company, which was filed with the SEC on August
21, 2008.
Forward-Looking Statements
This communication contains forward-looking statements. Those forward-
looking statements include all statements other than those made solely with
respect to historical fact. Forward-looking statements may be identified by
words such as “believes”, “expects”, “anticipates”, “estimates”, “projects”,
“intends”, “should”, “seeks”, “future”, continue”, or the negative of such
terms, or other comparable terminology. Such statements include, but are not
limited to, statements about the expected benefits of the transaction
involving Allscripts, Misys Healthcare Systems, LLC and Misys, including
potential synergies and cost savings, future financial and operating results,
and the combined company’s plans and objectives. In addition, statements made
in this communication about anticipated financial results, future operational
improvements and results or conditions and approvals are also forward-looking
statements. Such forward-looking statements are subject to numerous risks,
uncertainties, assumptions and other factors that are difficult to predict and
that could cause actual results to vary materially from those expressed in or
indicated by them. Such factors may include, but are not limited to: (1) the
occurrence of any event, development, change or other circumstances that could
give rise to the termination of the merger agreement; (2) the outcome of any
legal proceedings that have been or may be instituted against Allscripts,
Misys or MHS and others following announcement of entering into the merger
agreement; (3) the inability to complete the proposed transaction due to the
failure to obtain stockholder or shareholder approval or the failure of any
party to satisfy other conditions to completion of the proposed transaction;
(4) risks that the proposed transaction disrupts current plans and operations
and potential difficulties in employee retention as a result of the merger;
(5) the ability to recognize the benefits of the merger; (6) legislative,
regulatory and economic developments; and (7) other factors described in
filings with the Securities and Exchange Commission. Many of the factors that
will determine the outcome of the subject matter of this communication are
beyond Allscripts’, Misys’ and MHS’ ability to control or predict. Allscripts
can give no assurance that any of the transactions related to the merger will
be completed or that the conditions to the transactions will be satisfied.
Allscripts undertakes no obligation to revise or update any forward-looking
statement, or to make any other forward-looking statements, whether as a
result of new information, future events or otherwise. Allscripts is not
responsible for updating the information contained in this communication
beyond the published date, or for changes made to this communication by wire
services or Internet service providers.
SOURCE Allscripts Healthcare Solutions, Inc.